Irinotecan hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.

IS-741 (Fuzapladib, IS741) is a synthetic anti-inflammatory agent that shows inhibitory effect on cytosolic phospholipase A2 (cPLA2)..

ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects .

ISA27 is a novel small molecule that blocks p53-MDM2 interaction and induces apoptosis both in vitro and in vivo.

Isatin is an endogenous MAO inhibitor.

Isavuconazole(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata.

Isavuconazonium is a water-soluble prodrug form of the azole antifungal isavuconazole (ISA).

Isepamicin

Isepamicin Sulphate is an aminoglycoside antibiotic, which inhibits bacterial protein synthesis by targeting the bacterial 30S ribosomal subunit.

ISO-66 is a novel, highly stable, small-molecule MIF inhibitor that inhibits MIF tautomerase activity with IC50 of 1.4 uM.

ISO-92 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity with IC50 of 0.55 uM..

Isoastragaloside IV is a triterpene oligoglycoside isolated from Astragali Radix.

Isobavachalcone is a natural chalcone first isolated from P. corylifolia that displays antibacterial, antifungal, anticancer, anti-reverse transcriptase, antitubercular, and antioxidant activities in various research models.

Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), produces ROS, and induces cytotoxicity in cancer cells in an NQO1-dependent manner.

Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro.

Isocryptotanshinone is a potent signal transducer and activator of transcription 3 (STAT3) and protein tyrosine phosphatase 1B PTP1B inhibitor, with an IC50 of 56.1 μM for PTP1B.

Isoginkgetin (Iso-ginkgetin.

Isoliquiritigenin

Isoliquiritin has significant antidepressant-like, antifungal and anti-cancer activities. It induces apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells and inhibit the p53-dependent pathway and showed crosst

Isomaltose is a glucose disaccharide with an α-(1→6) linkage, as opposed to the α-(1→4) linkage found in maltose.

Isomangiferin is the major tetracyclic oxindole alkaloid components of Uncaira species, inhibits NMDA receptor with IC50 of 43.2 uM, also blocks calcium channel.

Isomigrastatin (iso-Migrastatin) is an analogue of migrastatin that shows potent antiproliferative effect on tumor cell lines and selectively inhibits translation.

Isoniazid is an antibacterial agent used primarily as a tuberculostatic.Target: AntibacterialIsoniazid is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in M. tuberculosis is called KatG [1]. KatG couples the isonicotinic acyl with NADH to form isonicotinic acyl-NADH complex. This complex binds tightly to the enoyl-acyl carrier protein reductase known as InhA, thereby blocking the natural enoyl-AcpM substrate and the action of fatty acid synthase. This process inhibits the synthesis of mycolic acid, required for the mycobacterial cell wall. A range of radicals are produced by KatG activation of isoniazid, including nitric oxide, which has also been shown to be important in the action of another antimycobacterial prodrug PA-824 [2, 3]. Isoniazid is bactericidal to rapidly dividing mycobacteria, but is bacteriostatic if the mycobacteria are slow-growing [4].

Isonicotinic acid is a metabolite of isoniazid. It is an isomer of nicotinic acid.

Isoquercitrin is an effective antioxidant and an eosinophilic inflammation suppressor.

Isoquercitrin is an inhibitor of Wnt/β-catenin that acts downstream of the β-catenin nuclear translocation; it is also a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders.

Isoscopoletin possesses inhibitory activity against hepatitis B virus (HBV) replication; it also shows substantial inhibition against multi-drug resistant CEM/ADR5000 cells and human CCRF-CEM leukaemia cells, with the IC50 value is 1.6 and 4.0 microM, res

Isosilybin is a flavanolignan found in the extract of S. marianum fruits with antioxidant and anticancer activities.It inhibits lipid peroxidation in rat liver microsomes (IC50 = 32 μM) and reduces ADP/Fe3+-induced malondialdehyde (MDA) production and lac

Isosorbide mononitrate(Isosorbide-5-mononitrate) is a nitrate-class compound used for angina pectoris; acts by dilating the blood vessels so as to reduce the blood pressure.

Isosteviol is a derivative of stevioside, a constituent of Stevia rebaudiana, which is commonly used as a noncaloric sugar substitute in Japan and Brazil.

Isotanshinone I has inhibitory activity against α-glucosidase and formation of AGE, with IC50s of 1.13, 0.432 μM for α-glucosidase and AGE, respectively.

Isotanshinone IIA, an abietane-type diterpene metabolite, could non-competitively inhibit Protein Tyrosine Phosphatase 1B (PTP1B) activity with an IC50 0f 11.4 μM.

Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM.

Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne. It was first developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.

Isovitexin, a food phytochemical contained in dietary rice products, it exhibits in vivo α-glucosidase inhibition, it possesses antihyperglycemic, neuroprotective, anti-inflammatory and anti-oxidant activities. Isovitexin inhibited xanthine oxidase with a

Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM.

iST2-1 is a first-in-class, in vivo active ST2 (suppression of tumorigenicity 2) inhibitor with IC50 of 56.14 and 54.62 uM in AlphaLISA and the HEK-Blue IL-33 assay, respectively.

iST2-2 is a novel ST2 (suppression of tumorigenicity 2) inhibitor active in vivo.

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

It is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.

ITI-214 is a potent, selective phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITZ-1 is a client-selective Hsp90 inhibitor that efficiently induces heat shock factor 1 (HSF1) activation, selectively inhibits IL-1β-induced MMP-13 production (IC50=0.51 uM) via inhibition of ERK activation.

IU1 is a selective USP14 inhibitor. IU1 prevents ventilator-induced lung injury in rats.

IU1-47 is a potent, selective small-molecule inhibitor of USP14 with IC50 of 0.6 uM, shows 10-fold more potent over IU1 and retains specificity for USP14; accelerates the rate of degradation of wild-type tau, the pathological tau mutants P301L and P301S, and the A152T tau variant in primary neuronal cultures, a specific residue in tau, lysine 174, is critical for the IU1-47-mediated tau degradation by the proteasome; stimulates autophagic flux in primary neurons.

Ivabradine, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

IWP-O1 is a porcn inhibitor with an EC50 value of 80 pM in a cultured cell reporter assay of Wnt signaling and effectively suppresses the phosphorylation of Dvl2/3 in HeLa cells.

J-113397 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor/ORL1) antagonist with IC50 of 2.3 nM.

J-147 is a potent neuroprotective and neurotrophic compound.

J8-C8 is a small-molecule inhibitor of bacterial N-acyl-homoserine lactone synthase (acyl-HSLs) TofI with IC50 of 35 uM for toxoflavin production.

JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM).

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectiv

JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM.

JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.

Jarin-1 is the first small-molecule inhibitor of JAR1 (IC50=3.8 uM) that inhibits jasmonate responses in Arabidopsis thaliana.

JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.

JBJ-01-162-04 is a small molecule targeting the flavivirus E protein with broad-spectrum activity, shows activity against DENV in the infectivity assay with IC90 of 0.1 uM.

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JCP251 is a selective small molecule inhibitor of S. aureus serine hydrolase FphB, effectively reduces infectivity in vivo..

JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.

Jervine(11-Ketocyclopamine) is a naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog(Shh) signaling; Jervine is an inhibitor of Smo.

JF5 (PAR1 inhibitor JF5) is an allosteric inhibitor of PAR1 that binds to helix 8 of the receptor.

JH-IX-179 is a novel highly potent and selective type I ATP competitive pan-FLT3 inhibitor with IC50 of 4 and 10 nM for FLT3-ITD and D835Y, respectively.

JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM (sirtuin deacylation activity), increase intracellular K-Ras4a lysine fatty acylation.

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

JH-XI-10-02 is a CDK8 PROTAC based on the CDK8 inhibitor JH-VIII-49, induces partial degradation of CDK8 in Jurkat cells with IC50 of 159 nM..

JI051(JI-051) is a specific compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JI130 (JI-130) is a specific Hse1 inhibitor that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases.

JM6 (KMO inhibitor JM6) is an orally bioavailable small-molecule prodrug of Ro 61-8048, which is an inhibitor of kynurenine 3-monooxygenase (KMO).

JMV 2959 (AEZS-123) is a potent ghrelin receptor (GHS-R1A) antaognist with binding IC50 of 32 nM.

JNc-440 is a small molecule that significantly and specifically strengthens the TRPV4-KCa2.3 interaction in mouse endothelial cells, but does not systemically activate TRPV4 and KCa2.3.

JND3229 is a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy (IC50 = 5.8 nM).

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 39220675 is potent and selective, brain penetrant H3 antagonist with Ki of 1.4 nM, pA2 of 9.42 for hH3.

JNJ-10198409 is a highly potent, selective PDGFRβ inhibitor with IC50 of 4.2 nM.

JNJ16567083 (EMQMCM) is a potent and selective mGluR1 antagonist that shows neuroprotective effects in some hypoxia-ischemia models.

JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-1A is a novel Dengue virus (DENV) NS4B inhibitor that inhibits DENV-2 sub-genomic replicon at 0.7 μM, in the absence of cytotoxicity.

JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures.

JNJ-26993135 is a potent, selective leukotriene A4 hydrolase (LTA4H) inhibitor, inhibits both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H with IC50 of 10 nM.

JNJ-28307474 is a potent, selective antagonist of the histamine H4 receptor (H4R), inhibits LPS-induced TNF production..

JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.

JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R)..

JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents).

JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM.

JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively.

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM.

JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively.

JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor..

JNJ-39933673 is a potent, selective SGLT2 inhibitor..

JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation..

JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively.

JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A.

JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively.

JNJ4796 (JNJ 4796, JNJ-4796) is an orally active small-molecule fusion inhibitor of influenza virus hemagglutinin (HA) with EC50 of 33 nM (H1N1 neutralization).

JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively.

JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.

JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM..

JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety..

JNJ525 is a small molecule inhibitor of TNFα that prevents the formation of TNFα complexes with TNFR1 and TNFR2 with IC50 of 1.2 uM and 1.1 uM in the TR-FRET assay, respectively..

JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV.

JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4.

JPC-3210 is a potent antimalarial agent with IC50 of 2.5-19 nM, remains activity against multidrug-resistant Plasmodium falciparum lines with little cytotoxicity in mammalian cell lines.

JPH203 (KYT-0353) is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition), but not LAT2.

JQ1-VHL-PROTAC is a novel PROTAC synthesis..

JQ-35, (S)- is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.

JSF-4088 (JSF4088) is a novel antitubercular agent with potent in vitro antitubercular potency (MIC=19 nM), with no significant Vero cell cytotoxicity (CC50 >120 uM)..

JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).

JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.

JTE-852 is a novel potent, selective, ATP-competitive Syk kinase inhibitor with IC50 of 1.25/1.28 nM for human/rat Syk, respectively.

JTE-952 (JTE952) is a potent, selective colony stimulating factor-1 receptor (CSF1R) type II inhibitor with IC50 of 14 nM, shows cellular activity in BMMCs IL-6 secretion assays with IC50 of 20 nM.

JTP-117968 is a novel orally available, selective glucocorticoid receptor modulator (SGRM) with IC50 of 6.8 nM.

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

Juniferdin is a small molecule, potent Protein disulfide isomerase (PDI) inhibitor with IC50 of 156 nM, inhibits PDI-mediated reduction of HIV-1 envelope glycoprotein gp120.

JVW-1034 is a selective small molecule modulator of σ2R/Tmem97 with Ki of 23 nM, 10-fold weaker affinity for σ1R (Ki=248 nM).

JW 642 (JW642) is a potent, selective monoacylglycerol lipase (MAGL) inhibitor with IC50 of 7.6, 14 and 3.7 nM for mouse, rat and human MAGL, respectively.

JW-7-25-1 is a potent MELK inhibitor with biochemical IC50 of 5.0 nM, also inhibits PIK3CA, mTOR, GSK3A and CDK7 with CI50 of 5-60 nM.

JYL-1421 (SC-0030) is a potent, competitive TRPV1 receptor antagonist with Ki of 53.5 nM, antagonizes capsaicin-induced calcium uptake with EC50 of 9.2 nM.

JZL 195 is a potent inhibitor of both FAAH and MAGL (IC50 = 2 and 4 nM, respectively).

JZL184 is a strong and selective inhibitor of Monoglyceride Lipase

K00546 is a potent inhibitor of the CDC2-like kinase CLK1 and CLK3 with IC50 of 8.9 and 29.2 nM, respectively..

K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 μM , while no inhibition of SphK1 at concentrations up to 10 μM. IC50 value: 4.3 uM.

K-604 is a potent, selective and competitive ACAT-1 inhibitor with IC50 of 0.45 uM for human ACAT-1, displays 229-fold selectivity over ACAT-2.

K67 is a specific inhibitor of the interaction between S349-phosphorylated p62 and Keap1, exhibts no inhibitory effect on the interaction of full-length Keap1 with Nrf2-ETGE or full-length Nrf2.

K-777 is a potent and selective CCR4 antagonist that inhibits both CCL17 binding and CCL17-induced chemotaxis in Hut78 cells with IC50 of 57 and 8.9 nM respectively.

K-8986 maleate (K8986) is a histamine H1-receptor antagonist with potential therapeutic for treatment of allergic conjunctivitis..

Kaempferol-3-glucoside is an orally bioavailable flavonoid that has been isolated from the leaves of D. kaki and R. agrestis and has anti-inflammatory activity.

Kaitocephalin (PF 1191) is a non-selective ionotropic glutamate receptor (iGluR) antagonist, the first discovered natural toxin with protective properties against excitotoxic-death of cultured neurons induced by NMDA or AMPA/kainate receptors.

KAN0438241 (KAN-0438241) is a potent, selective PFKFB3 inhibitor with IC50 of 0.19 uM, 20-fold selectivity over PFKFB4 and no significant inhibition on PFKFB1 and 2..

KAN0438757 (KAN-0438757) is a potent, selective PFKFB3 inhibitor, the ester prodrug of KAN0438241 with enhanced cell permeability.

Kanamycin sulfate(Kanamycin monosulfate) is an aminoglycoside antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

KAR-5417 is a potent, selective TPH1 (tryptophan hydroxylase-1) inhibitor with IC50 of 33 nM.

KAR-5585 (Rodatristat) is the prodrug of the potent TPH1 inhibitor KAR5417, shows robust reduction of intestinal serotonin (5-HT) levels in mice.

Karonudib (TH1579) is an analogue of TH588, a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo..

Kartogenin(KGN) is a small molecule stimulator of chondrogenesis; promotes chondrocyte differentiation(EC50=100 nM) and binds to filamin A.

KB SRC 4 (c-Src-IN-4) is a potent, highly selective c-Src kinase inhibitor with Ki of 44 nM, does not inhibit c-Abl up to 125 uM, and binds to c-Src-TM (Q275G, C277Q, F278Y) with similar potency to that of wild-type c-Src.

kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).

KBP-5074 (KBP5074) is a novel non-steroidal, highly selective mineralocorticoid receptor antagonist for the treatment of hypertensive chronic kidney disease..

KB-R7943 mesylate is a potent, selective inhibitor of the reverse mode of the Na+/Ca2+ exchanger (IC50 = 0.7 mM).

KC01 is a potent and selective inhibitor of ABHD16A with IC50 of 90 nM for hABHD16A, 520 nM for mABHD16A.

KCI807 (KCI-807) is a lead molecule that selectively disrupts ELK1-dependent promoter activation by wild-type and variant Ars (IC50=0.53 uM) without interfering with ELK1 activation by ERK.

KCN1 (HIF inhibitor KCN1) is a small molecule inhibitor of the HIF-1 pathway, antagonizes HIF transcription in bioassay, blocks the p300/HIF-1α interaction, and exert potent anticancer activity in vitro and in vivo.

KDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481, >20-fold selectivity over KDM4A..

KDM5A covalent inhibitor N73 is the the isopropyl ester derivative of N71, an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481, >20-fold selectivity over KDM4A..

KDM5-C49 is a potent, selective KDM5 inhibitor with IC50 of 25, 30 and 59 nM for KDM5A, B and C, respectively.

KDM5-C70 is the cell-permeable derivative of KDM5-C49, potent, selective and cell permeable KDM5 inhibitor with IC50 of 0.3, 0.3 and 0.58 uM for KDM5A, B and C, respectively.

KDM-IN-6 is a potent, highly selective and cell-active inhibitor of KDM2A/7A with IC50 of 0.16 and 0.19 uM,respectively.

KDOAM25 is a selective inihbitor of the KDM5 family histone demethylases JARID1A, JARID1B, JARID1C and JARID1D with IC50 values < 60 nM.

KDS2010 (KDS-2010, KDS 2010) is a potent, highly selective, reversible Monoamine oxidase-B (MAO-B) inhibitor with IC50 of 7.6 nM.

KDU731 is a potent, selective parasite Cryptosporidium lipid kinase PI4K (phosphatidylinositol-4-OH kinase) inhibitor with IC50 of 25 nM, displays >50-fold selectivity window against the human PI4K IIIβ homologue.

Kelatorphan is a full inhibitor of enkephalin degrading enzymes.

Ketoprofen (Actron) is a non-selective NSAID with IC50 of 0.5 μM and 2.33 μM for human recombinant COX-1 and COX-2, respectively.

Kevetrin (thioureidobutyronitrile), is a water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.

KG-548 is an ARNT/TACC3 disruptor (IC50=25 uM) that selectively bind within the ARNT PAS (Per-ARNT-Sim) domain that recruits TACC3..

KGA-2727 is a potent, selective SGLT1 inhibitor with Ki of 97.4 nM, >100-fold selectivity over SGLT2.

KGP-420 is the water-soluble phosphate prodrug of KGP-94 in vivo studies, KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM.

KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM, shows no significant inhibitory effect on cathepsin B (IC50>10 uM).

KH-176 (KH176, Sonlicromanol) is a smal molecule ROS-redox modulator, effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system.

KH176 is a chemical entity derivative of Trolox and small molecule ROS-redox modulator, shows potential treatment for mitochondrial disorders.

KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays.

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1), displays almost 100-fold selectivity against the CLK3 isoform.

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 (TACC3).

KI16 is a novel small molecules that inhibit STAT3-dependent transcription and function, interacts with the STAT3 SH2 domain.

Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation..

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

KIN-281 is a small molecule that inhibits multiple kinases including MELK and the non-receptor tyrosine kinase BMX with IC50 of 1.4 and 1.9 uM, respectively.

Kinetin (6-Furfuryladenine)

KIRA6 is an ATP-competitive IRE1α kinase inhibiting RNase attenuator (KIRA) that allosterically inhibits IRE1α RNase kinase activity (IC50 = 0.6 µM) and prevents oligomerization.

KIRA-7 is a small molecule inhibitor of IRE1α kinase/Rnase with IC50 of 0.11/0.22 uM, allosterically inhibits IRE1α RNase activity.

Kira8 is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α’s RNase.

KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

KL001 (KL-001) is a small molecule that specifically interacts with cryptochrome (CRY) and small molecule modulator of the circadian clock.

SEC inhibitor KL-1 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=3.48 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P

SEC inhibitor KL-2 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=1.50 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P

KMN-159 is a potent prostaglandin E2 type 4 (EP4) receptor agonist with Ki of 0.38 nM and shows five fold increase in potency versus KMN-80.

KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.

kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM.

Kojic acid is a natural substance produced by Aspergillus oryzae, also used as an anti-oxidant and radio-protective agent.

KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.